Clinical Trials
68 trialsNeoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
M.D. Anderson Cancer Center
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
ARAMON
Bayer
CheckMate 9KD
Bristol-Myers Squibb
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ARROW
Progenics Pharmaceuticals, Inc.
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Pfizer
Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
Case Comprehensive Cancer Center
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
ZZ-First
MedSIR
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
Astellas Pharma Inc
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
M.D. Anderson Cancer Center
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Pfizer
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
Astellas Pharma Inc
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
Astellas Pharma Inc
ENACT
Astellas Pharma Inc
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Astellas Pharma Inc
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
University of Rochester
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Medical University of South Carolina
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy
OHSU Knight Cancer Institute
BonEnza
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
ARB
Queen Mary University of London
CHEIRON
Santa Chiara Hospital
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
Icahn School of Medicine at Mount Sinai
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Enzalutamide + External Beam Rt For Prostate
Dana-Farber Cancer Institute
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Memorial Sloan Kettering Cancer Center
GREKO III
Grupo Español de Tumores Huérfanos e Infrecuentes
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
Dana-Farber Cancer Institute
Restore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
The European Uro-Oncology Group
Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide
The European Uro-Oncology Group
STARVE-PC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.
Osaka City University
Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
University of Colorado, Denver
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
Eli Lilly and Company
EXCALIBUR
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Cedars-Sinai Medical Center
Transformer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
University of Utah